New biotech Slate Medicines raises $130M for migraine drug from China

Ali Nemati5 days ago28 sec read11 views

Slate Medicines, a Chinese biotech startup, secured $130 million in Series A funding to develop a new class of migraine drugs, joining global efforts in this therapeutic area. This investment underscores growing international interest and competition in addressing unmet needs for effective migraine treatments. For content creators, the focus on innovative drug development highlights opportunities in reporting on emerging biotech trends and startup successes from China.

Read the full article at Endpoints News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

Comments

OpenAI's record funding is essentially everyone against Google in the AI race

OpenAI raised a record $110 billion from major tech rivals of Google like Amazon and Nvidia, positioning itself to challenge Google's dominance in AI....OpenAI raised a record $110 billion from major tech rivals of Google like Amazon and Nvidia, positioning itself to challenge Google's dominance in AI. This funding underscores the competitive landscape where other tech giants are aligning against Goo...

Ali Nemati

Biotech & Pharma2 days ago27 sec read

STAT+: Pharmalittle: We're reading about FDA and a 'smear campaign,' Cigna buying a large pharmacy, and more

The U.S. FDA Commissioner Marty Makary defended recent rejections of rare disease drugs and top official Vinay Prasad against a perceived "smear campa...The U.S. FDA Commissioner Marty Makary defended recent rejections of rare disease drugs and top official Vinay Prasad against a perceived "smear campaign," while Cigna acquired CarepathRx to strengthen its control over pharmaceutical distribution in ...

Ali Nemati

Startups & VC2 days ago32 sec read

Sector Snapshot: Space Tech Startup Funding Still Flying High

Space tech startups continue to secure significant funding, with more than two dozen companies raising over $100 million each in the past year, and Sp...Space tech startups continue to secure significant funding, with more than two dozen companies raising over $100 million each in the past year, and SpaceX reportedly aiming for a $1.5 trillion valuation in an upcoming IPO. This trend contrasts with o...

Ali Nemati

Biotech & Pharma3 days ago27 sec read

STAT+: FDA Commissioner Marty Makary defends rare disease drug rejections, Vinay Prasad

FDA Commissioner Marty Makary defended recent rejections of rare disease drugs and top FDA official Vinay Prasad against criticism, emphasizing the ag...FDA Commissioner Marty Makary defended recent rejections of rare disease drugs and top FDA official Vinay Prasad against criticism, emphasizing the agency's commitment to rigorous standards despite pressure for approvals. This stance underscores the ...

Ali Nemati

Biotech & Pharma3 days ago33 sec read

STAT+: Pharmalittle: We're reading about a puzzling FDA rejection, a Lilly weight loss pill, and more

An experimental therapy for a rare blood cancer, Ebvallo, was unexpectedly rejected by the FDA despite internal recommendations for approval, indicati...An experimental therapy for a rare blood cancer, Ebvallo, was unexpectedly rejected by the FDA despite internal recommendations for approval, indicating a potentially higher approval threshold for rare disease treatments. Direct-to-consumer websites ...

Ali Nemati

New biotech Slate Medicines raises $130M for migraine drug from China

Related Articles

OpenAI's record funding is essentially everyone against Google in the AI race

STAT+: Pharmalittle: We're reading about FDA and a 'smear campaign,' Cigna buying a large pharmacy, and more

Sector Snapshot: Space Tech Startup Funding Still Flying High

STAT+: FDA Commissioner Marty Makary defends rare disease drug rejections, Vinay Prasad

STAT+: Pharmalittle: We're reading about a puzzling FDA rejection, a Lilly weight loss pill, and more